Ulcerative (chronic) rectosigmoiditis without complications
Methodology & AI Transparency ⓘ
Ulcerative (chronic) rectosigmoiditis without complications Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as K51.30, Ulcerative (chronic) rectosigmoiditis without complications falls under IBS, IBD & Colon management, where fecal calprotectin inflammatory in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: differentiation) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry K51.30: Ulcerative (chronic) rectosigmoiditis without complications is managed within IBS, IBD & Colon.
- 3 Typical cash cost range: Primary evaluation for Ulcerative (chronic) rectosigmoiditis without complications incorporates fecal calprotectin inflammatory in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: differentiation) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Ulcerative (chronic) rectosigmoiditis without complications monitoring tracks Tissue Transglutaminase IgA in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: (tTG-IgA)) toward Negative (celiac rule-out) (K51.30).
Ask our AI Specialists anything about Ulcerative (chronic) rectosigmoiditis without complications
What Is Ulcerative (chronic) rectosigmoiditis without complications?
Designated in federal medical registries as K51.30, Ulcerative (chronic) rectosigmoiditis without complications falls under IBS, IBD & Colon management, where fecal calprotectin inflammatory in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: differentiation) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Ulcerative (chronic) rectosigmoiditis without complications (K51.30) center on mucosal tight-junction permeability in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: shifts or immune-mediated). targeted ibs, ibd & colon interventions aim to normalize Tissue Transglutaminase IgA in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: (tTG-IgA)).
Common Symptoms & Clinical Signs
- • Presentation of Ulcerative (chronic) rectosigmoiditis without complications (K51.30): alternating diarrhea, constipation, in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: urgency, or sensation)
- • Secondary Ulcerative (chronic) rectosigmoiditis without complications clinical sign: post-meal abdominal distension, in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: gas bloating, or)
- • Symptom flares in Ulcerative (chronic) rectosigmoiditis without complications correlating with Tissue Transglutaminase IgA in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: (tTG-IgA)) deviation outside Negative (celiac rule-out) (K51.30)
- • Functional ibs, ibd & colon impact requiring fecal calprotectin inflammatory in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: differentiation) evaluation (K51.30)
Ulcerative (chronic) rectosigmoiditis without complications Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K51.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | IBS, Crohn, Colitis & Bowel Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Tissue Transglutaminase IgA in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: (tTG-IgA)) | Negative (celiac rule-out) (K51.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP, CBC & in Ulcerative (chronic) rectosigmoiditis without complications (K51.30: Ferritin) | Normal hemoglobin; hs-CRP < 1.0 mg/L (K51.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fecal Calprotectin [Ulcerative (chronic) rectosigmoiditis without complications K51.30] | < 50 mcg/g (K51.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ulcerative (chronic) rectosigmoiditis without complications
Treatment selection for Ulcerative (chronic) rectosigmoiditis without complications depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ulcerative (chronic) rectosigmoiditis without complications)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor: What a 1,139-Participant Study Found Tofacitinib was efficacious in patients with UC regardless of prior TNFi failure status. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-03-15 • Phase III Randomized Trial | N = 1,139 | 96/100 | PMID 33684552 ↗ |
| New Insights on Long-term safety and real-world benefits of filgotinib for the treatment of: What a 250-Participant Study Found Filgotinib induced and maintained symptomatic full symptom relief and improved HRQoL over 4 years. Alimentary pharmacology & therapeutics • 2024-09-15 • Phase III Randomized Trial | N = 250 | 93/100 | PMID 39086130 ↗ |
| New Insights on Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events: What a 787-Participant Study Found Patients receiving etrasimod demonstrated no increased risk of infection. Journal of Crohn's & colitis • 2024-10-15 • Phase III Randomized Trial | N = 787 | 93/100 | PMID 38700040 ↗ |
| Can This Approach Help? Inside the Latest Research on Therapeutic Modulation of IL-6/STAT-3 and Nitric Oxide by Fenofibrate in Patients Fenofibrate may represent a promising add-on therapy in patients with mild-to-moderate UC by modulating inflammation and improving QoL. Pharmacotherapy • 2025-12-15 • Phase III Randomized Trial | N = 60 | 88/100 | PMID 41330887 ↗ |
| Can This Approach Help? Inside the Latest Research on Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Over 50% of initial nonresponders achieved clinical response with extended risankizumab treatment. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2026-05-15 • Phase III Randomized Trial | N = 68 | 88/100 | PMID 40953785 ↗ |
Ulcerative (chronic) rectosigmoiditis without complications Patient Community & “People Like Me” Threads
Filter Ulcerative (chronic) rectosigmoiditis without complications community threads and patient logs by age, biological sex, dosage, and treatment duration.